| "A female patient showed signs of osteomyelofibrosis after being treated for 70 months." | ( Jäckle, B; Maas, D; Raif, W; Schramm, A; Schubothe, H, 1979) |
| "One patient with myelofibrosis improved dramatically with placebo therapy alone, no longer requiring frequent transfusions because of a hemoglobin level increase from 5." | ( Amsden, TW; Branda, RF; Jacob, HS, 1977) |
| "A case of acute myelofibrosis occurring in the course of long-term chlorambucil therapy for cardiac manifestations of progressive systemic sclerosis (PSS) is reported." | ( Chung, KB; Gisser, SD, 1979) |
| "A 64 year-old female patient of idiopathic myelofibrosis (IMF), who had had rapidly progressing massive splenomegaly and severe pancytopenia refractory to blood transfusion, was treated with PSL 0." | ( Ikeda, Y; Kubo, A; Masuda, Y; Michikawa, N; Ogawa, T; Tanosaki, R; Uchida, H, 1992) |
| "A 69-year-old man with agnogenic myeloid metaplasia was treated with interferon-alpha 2 as part of a Phase II clinical trial." | ( Buckley, P; Duffy, TP; Radin, AI, 1991) |
| "IHS with myelofibrosis is usually considered as unresponsive to corticotherapy." | ( Capodano, AM; Fossat, C; Guitard, AM; Michel, G; Mozziconacci, MJ; Perrimond, H; Scheiner, C; Thuret, I, 1991) |
| "A 68-yr-old male with agnogenic myeloid metaplasia was given phosphorus-32-colloidal chromic phosphate intrapericardially for the treatment of malignant pericardial effusion." | ( McDermott, RL; Sprengelmeyer, JT, 1990) |
| "A patient with secondary myelofibrosis associated with prostatic cancer gained hematologic remission after hormone therapy." | ( Fukuchi, M; Ishimura, J, 1990) |
| "Two cases of idiopathic myelofibrosis of childhood were treated with intravenous methylprednisolone." | ( Ozsoylu, S; Ruacan, S, 1986) |
| "The case of a patient with myelofibrosis who developed polycythaemia vera after corticosteroid therapy, splenectomy and Busulphan therapy is reported." | ( Bizzi, B; Leone, G; Marra, R; Pagano, L; Rabbitti, C; Storti, S; Teofili, L, 1988) |
| "Three patients with chronic idiopathic myelofibrosis have responded to busulfan treatment with an excellent hematologic remission and reversal of myelofibrosis and myeloid metaplasia." | ( Chang, JC; Gross, HM, 1988) |
| "Bone marrow myelofibrosis may be another delayed treatment effect of this class of drugs." | ( Fehir, KM; McKenney, SA, 1986) |
| "A patient with myelofibrosis transforming into acute non-lymphocytic leukaemia (ANLL) was treated with low doses of cytosine arabinoside (ARA-C)." | ( Ahlbom, G; Jensen, MK; Johansen, P, 1986) |
| "12 patients with symptomatic chronic myelofibrosis were treated with either busulphan or 6-thioguanine." | ( Manoharan, A; Pitney, WR, 1984) |
| "The responses of 23 patients with agnogenic myeloid metaplasia (AMM) to androgen therapy were studied." | ( Besa, EC; Gardner, FH; Geller, NL; Nowell, PC, 1982) |
| "A case of myelofibrosis related to thorotrast administration is described." | ( Arnold, AG; Oelbaum, MH, 1980) |
| "A patient with idiopathic myelofibrosis is reported who developed a drug fever after treatment with hydroxyurea, a generally effective and well-tolerated drug in chronic myeloproliferative syndromes." | ( Fickers, MM; Pannebakker, MA; Starmans-Kool, MJ, 1995) |
| "The progression towards myelofibrosis (spent phase, post polycythaemia myeloid splenomegaly) increases with the duration of the disease and the frequency of transformation differs according to the type of treatment." | ( Rain, JD, 1994) |
| "This case was considered to be an acute myelofibrosis developed from myelodysplastic syndrome and worth to reporting with a review of literature, because drastic combination chemotherapy was extremely effective." | ( Fujita, H; Hirayama, M; Kohgo, Y; Kura, T; Mogi, Y; Nakaya, R; Niitsu, Y; Tsuji, N; Watanabe, N, 1993) |
| "These findings indicated that her myelofibrosis was the result of secondary hyperparathyroidism, and that this complication is potentially reversible if accurate treatment is given." | ( Harada, T; Katagiri, M; Nagahana, H; Nomura, S; Ogawa, Y; Osawa, G, 1996) |
| "A 55-year-old man with myelofibrosis was treated with natural alpha-interferon with a good hematologic response." | ( Andoh, A; Bamba, T; Fujiyama, Y; Hodohara, K; Minamiguchi, H; Nakamura, F, 1997) |
| "Improvement in bone marrow fibrosis was noted in two of five available post-treatment marrow examinations." | ( Li, CY; Silverstein, MN; Tefferi, A, 1997) |
| "A patient with myelofibrosis complicated by recurrent candidemia died despite treatment with amphotericin B and fluconazole." | ( Matsumura, M; Mori, T; Oguri, T, 1998) |
| "We report a case of fulminant myelofibrosis after administration of fludarabine in a patient diagnosed as having refractory low-grade lymphoma, progressing fatally." | ( Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ, 1998) |
| "The focus was on whether myelofibrosis is associated with the PEG-rHuMGDF treatment in this chemotherapy model." | ( Harada, K; Ide, Y; Imai, A; Yanagida, M, 1999) |
| "In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d." | ( Ansell, SM; Call, TG; Camoriano, JK; Colon-Otero, G; Dewald, GW; Elliott, MA; Gray, LA; Hanson, CA; Kaufmann, SH; Mesa, RA; Pardanani, A; Schroeder, G; Steensma, DP; Tefferi, A, 2002) |
| "We report a case of myelofibrosis with myeloid metaplasia (MMM) that responded dramatically to oral busulfan treatment after failure of hydroxyurea." | ( Baumann, MA; Naqvi, T, 2002) |
| "Thirteen patients with idiopathic myelofibrosis (5 osteomyelosclerosis) were treated with recombinant human erythropoietin (rHuEpo) for transfusion-dependent anemia." | ( Clausen, NT; Hasselbalch, HC; Jensen, BA, 2002) |
| "In this context, myelofibrosis is secondary to plasmocyte invasion of the bone marrow and regresses, or disappears, following specific treatment of the myeloma." | ( Boucher, E; De Revel, T; Nedellec, G; Samson, T; Souleau, B; Védrine, L, 2002) |
| "A 70-year-old man with primary myelofibrosis was treated with hydroxycarbamide and blood transfusions." | ( Jonkhoff, AR; van der Valk, P; Zweegman, S, 2002) |
| "Controversial issues in chronic idiopathic myelofibrosis (IMP) are amongst others the evolution of the disease process and the influence of therapy on the dynamics of fibrosis." | ( Diehl, V; Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J, 2003) |
| "A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matched-sibling donor." | ( Ball, ED; Bashey, A; Broome, HE; Carrier, E; Hoh, CK; Holman, P; Lane, T; Sun, C; Tanner, ML, 2003) |
| "Development of myelofibrosis in IMF is obviously due to disease progression unrelated to stage at diagnosis and not significantly influenced by treatment modalities." | ( Diehl, V; Hülsemann, R; Kvasnicka, HM; Schmitt-Gräff, A; Thiele, J, 2004) |
| "The influence of Cladribin therapy to bone marrow fibrosis in patients with hairy cell leukemia was studied." | ( Dĕdic, K; Zák, P, 2004) |
| "The effect of imatinib therapy on bone marrow fibrosis was evaluated in 40 patients with chronic-phase CML who were treated after interferon-alpha failure." | ( Bueso-Ramos, CE; Cortes, J; Giles, F; Kantarjian, H; Medeiros, LJ; O'Brien, S; Rios, MB; Talpaz, M, 2004) |
| "We present a 9-year-old girl with known myelofibrosis whose headaches were unresponsive to routine treatment." | ( Blaser, S; Gilday, D; Haidar, S; Ortiz-Neira, C; Shroff, M, 2005) |
| "The conventional treatment of myelofibrosis involves a wait-and-see approach for asymptomatic patients, oral chemotherapy for the hyperproliferative forms of the disease, androgens or erythropoietin for the anaemia, and splenectomy in selected patients." | ( Cervantes, F, 2005) |
| "Forty-four patients who had myelofibrosis with myeloid metaplasia received treatment with thalidomide in a Phase II clinical trial at a dose of 200 mg daily with escalation by 200 mg weekly until the best tolerated dose (maximum, 800 mg) was reached." | ( Albitar, M; Cortes, JE; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, MJ; O'Brien, SM; Pierce, S; Thomas, DA; Verstovsek, S; Zeldis, J, 2006) |
| "Here, we discuss a patient with primary myelofibrosis and related transfusion-dependent anemia who received chelation therapy with the once-daily oral iron chelator, deferasirox." | ( Alberti, D; Angelucci, E; Deplano, S; Di Tucci, AA; Murru, R; Rabault, B, 2007) |
| "We report a patient with very advanced myelofibrosis and huge splenomegaly who showed a complete hematological response to low dose thalidomide with reversal of splenomegaly and bone narrow fibrosis after 30 months of the treatment." | ( Berrebi, A; Feldberg, E; Shvidel, L; Spivak, I, 2007) |
| "Since bone marrow biopsy revealed myelofibrosis, she received anabolic hormone therapy." | ( Kubota, Y; Waki, M, 2009) |
| "Eighty-four patients with myelofibrosis-associated anemia were randomly assigned to the aforementioned treatment arms: 22, 19, 22, and 21, respectively." | ( Barosi, G; Bekele, BN; Cervantes, F; Deeg, HJ; Gale, RP; Gisslinger, H; Kantarjian, HM; Kvasnicka, HM; Mesa, RA; Paquette, RL; Passamonti, F; Rivera, CE; Roboz, GJ; Tefferi, A; Thiele, J; Vardiman, JW; Verstovsek, S; Zhang, Y, 2009) |
| "Leukemic transformation (LT) from myelofibrosis has a very poor prognosis with the current treatment strategies." | ( Andersson, BS; Bueso-Ramos, C; Champlin, RE; Ciurea, SO; de Lima, M; Giralt, S; Hosing, CM; Popat, U; Saliba, R; Verstovsek, S, 2010) |
| "Fourteen patients with myelofibrosis were treated with sunitinib at a daily continuous dose of 37." | ( Apostolidou, E; Borthakur, G; Burger, I; Kantarjian, H; Thomas, D; Verstovsek, S, 2010) |
| "Treatment options for myelofibrosis are limited." | ( Al-Ali, HK; Barbui, T; Barosi, G; Cervantes, F; Gisslinger, H; Harrison, C; Hunter, DS; Kiladjian, JJ; Knoops, L; Levy, R; McQuitty, M; Stalbovskaya, V; Vannucchi, AM; Waltzman, R, 2012) |
| "Diagnosis of post-PV myelofibrosis is established according to the International Working Group for Myeloproliferative Neoplasms Research and Treatment criteria." | ( Passamonti, F, 2012) |
| "Hypercalcemia associated with myelofibrosis is rare, and its pathogenesis and treatment are not known." | ( Chang, J; Gru, AA; Khoury, N; Whyte, MP, 2012) |
| "COMFORT-I (Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment-I) is a double-blind, placebo-controlled phase III study evaluating ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis." | ( Catalano, JV; Deininger, MW; Erickson-Viitanen, S; Gotlib, J; Gupta, V; Hare, T; Harvey, JH; Kantarjian, HM; Levy, RS; Mesa, RA; Miller, CB; Sandor, V; Shields, AL; Silver, RT; Sun, W; Talpaz, M; Verstovsek, S; Winton, EF, 2013) |
| "The landscape of therapy for myelofibrosis (MF) is evolving at a pace not previously seen for this clonal myeloproliferative neoplasm." | ( Emanuel, R; Geyer, H; Gowin, K; Mesa, RA, 2013) |
| "In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment (COMFORT) studies, ruxolitinib, a potent Janus kinase 1 (JAK1)/JAK2 inhibitor, provided substantial improvements in splenomegaly, symptoms, quality-of-life measures and overall survival compared with placebo or best available therapy." | ( Akashi, K; Amagasaki, T; Depei, W; Du, X; Eom, KS; Gopalakrishna, P; Handa, H; Hou, HA; Hou, M; Hu, Y; Ito, K; Jianyong, L; Jie, J; Jung, CW; Kim, JS; Li, J; Liu, T; Ohishi, K; Okamoto, S; Oritani, K; Park, S; Saito, S; Shih, LY; Takenaka, K; Tauchi, T; Wang, MC; Xiao, Z; Zhou, D, 2015) |
| "In the COMFORT (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Therapy)-I study, the Janus kinase (JAK)1/JAK2 inhibitor ruxolitinib provided significant reductions in splenomegaly, improvements in myelofibrosis (MF)-related symptoms, and a survival advantage relative to placebo in patients with intermediate-2 or high-risk MF." | ( Atallah, E; Burn, T; Gotlib, J; Gupta, V; Mascarenhas, JO; Mesa, RA; Sandor, V; Sun, W; Verstovsek, S, 2015) |
| "The prognosis of myelofibrosis is poor and treatment is mainly palliative." | ( Anand, V; Martí-Carvajal, AJ; Solà, I, 2015) |
| "We report 12 Danish myelofibrosis patients who have been treated successfully with ruxolitinib despite having low platelet counts (< 50 × 10(9)/L) during their treatment-course." | ( Bjørn, ME; Hasselbalch, HC; Holmström, MO, 2016) |
| "In the phase 3 Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment-I trial, patients with MF, post-PV MF, or post-ET MF achieved significant reductions in splenomegaly and improvements in symptoms with ruxolitinib vs placebo at week 24." | ( Burn, TC; Deininger, M; Huber, R; Paranagama, D; Radich, J; Verstovsek, S, 2015) |
| "Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm where severity as well as treatment complexity is mainly attributed to a long lasting disease and presence of bone marrow stroma alterations as evidenced by myelofibrosis, neoangiogenesis, and osteosclerosis." | ( Desterke, C; Le Bousse-Kerdilès, MC; Martinaud, C; Ruzehaji, N, 2015) |
| "Discontinuation of ruxolitinib in myelofibrosis often induces 'withdrawal syndrome' characterized by acute relapse of the disease, but this issue is not well addressed in the treatment of GvHD." | ( Ago, H; Fujii, N; Ikeda, K; Inomata, T; Mori, Y; Teshima, T; Yoshimoto, G, 2016) |
| "Patients with myelofibrosis at intermediate-1 risk according to the International Prognostic Score System are projected to a relatively long survival; nonetheless, they may carry significant splenomegaly and/or systemic constitutional symptoms that hamper quality of life and require treatment." | ( Abruzzese, E; Benevolo, G; Bergamaschi, M; Binotto, G; Bonifacio, M; Breccia, M; Buccisano, F; Cavazzini, F; Cavo, M; Crugnola, M; Cuneo, A; Heidel, FH; Isidori, A; Kallenberg, L; Latagliata, R; Martino, B; Palandri, F; Palumbo, GA; Polverelli, N; Scaffidi, L; Sgherza, N; Spinsanti, M; Tieghi, A; Tiribelli, M; Vianelli, N, 2018) |
| "The phase III COMFORT (Controlled Myelofibrosis Study With Oral JAK inhibitor Treatment)-I and COMFORT-II trials in patients with intermediate-2 or high-risk myelofibrosis (MF) showed that ruxolitinib was superior to placebo and best available therapy, respectively, for improvements in spleen volume, MF-related symptoms, and overall survival (OS)." | ( Komrokji, RS; Mesa, RA; Miller, CB; Montgomery, M; Sun, W; Verstovsek, S, 2017) |
| "A 72-year-old man with myelofibrosis started treatment with ruxolitinib." | ( Ballesta, B; Ballesta, JJ; González, H; Martín, V, 2017) |
| "Conclusion In JAKi-naïve patients with myelofibrosis, 24 weeks of momelotinib treatment was noninferior to ruxolitinib for spleen response but not for symptom response." | ( Catalano, JV; Cervantes, F; Deng, W; Devos, T; Dubowy, RL; Egyed, M; Gotlib, J; Hellmann, A; Kiladjian, JJ; Maltzman, JD; McLornan, D; Mesa, RA; Shimoda, K; Winton, EF, 2017) |
| "The treatment landscape for myelofibrosis (MF) has reached the molecular era by targeting different pathways that are implied in this myeloproliferative neoplasm." | ( Diaz, AE; Mesa, RA, 2018) |
| "Patients who had myelofibrosis and previous ruxolitinib treatment for at least 28 days who either required red blood cell transfusions while on ruxolitinib or ruxolitinib dose reduction to less than 20 mg twice a day with at least one of grade 3 thrombocytopenia, anaemia, or bleeding at grade 3 or worse, with palpable spleen of at least 5 cm and without grade 2 or greater peripheral neuropathy were included in the study." | ( Cervantes, F; Dong, H; Gupta, V; Harrison, CN; Kawashima, J; Kiladjian, JJ; Lavie, D; Maltzman, JD; Passamonti, F; Platzbecker, U; Vannucchi, AM; Verstovsek, S; Winton, EF, 2018) |
| "In patients with myelofibrosis previously treated with ruxolitinib, momelotinib was not superior to BAT for the reduction of spleen size by at least 35% compared with baseline." | ( Cervantes, F; Dong, H; Gupta, V; Harrison, CN; Kawashima, J; Kiladjian, JJ; Lavie, D; Maltzman, JD; Passamonti, F; Platzbecker, U; Vannucchi, AM; Verstovsek, S; Winton, EF, 2018) |
| "A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms." | ( Ikeda, M; Kiyasu, J; Ogawa, Y; Shiratsuchi, M; Tsuda, M; Tsukamoto, Y; Yufu, Y, 2018) |
| "In patients with myelofibrosis and thrombocytopenia, including those with prior anti-JAK therapy, pacritinib twice daily was more effective than BAT, including ruxolitinib, for reducing splenomegaly and symptoms." | ( Al-Fayoumi, S; Callahan, JA; Daly, R; Drummond, M; Gerds, AT; Gotlib, J; Granston, T; Gupta, V; Harrison, C; Hoffman, R; Jamieson, C; Mascarenhas, J; Mesa, R; Pristupa, A; Singer, JW; Stein, B; Szoke, A; Talpaz, M; Verstovsek, S, 2018) |
| "In 12 patients with myelofibrosis (median age, 63 years; range, 43 to 71 years) who were treated with ruxolitinib and underwent allogeneic stem cell transplantation (ASCT), ruxolitinib was continued (2 × 5 mg daily) until stable engraftment." | ( Ayuk, F; Badbaran, A; Christopeit, M; Kröger, N; Shahnaz Syed Abd Kadir, S; Wolschke, C; Zabelina, T, 2018) |
| "Treatment of patients with myelofibrosis with the type I JAK (Janus kinase) inhibitor ruxolitinib paradoxically induces JAK2 activation loop phosphorylation and is associated with a life-threatening cytokine-rebound syndrome if rapidly withdrawn." | ( Babon, JJ; Barry, EF; Dottore, M; Hercus, TR; Hughes, TP; Kan, WL; Lathi, M; Liau, NPD; Lopez, AF; Majeti, R; Parker, MW; Ross, DM; Stomski, F; Tergaonkar, V; Thomas, D; Tvorogov, D, 2018) |
| "The management of patients with myelofibrosis (MF) has dramatically changed since the introduction of ruxolitinib as a tailored treatment strategy." | ( Baratè, C; Benevolo, G; Bonifacio, M; Breccia, M; Elli, EM; Guglielmelli, P; Maffioli, M; Malato, A; Mendicino, F; Palandri, F; Palumbo, GA; Pugliese, N; Ricco, A; Rossi, E; Rumi, E; Sant'Antonio, E; Tiribelli, M, 2020) |
| "HS was treated with splenectomy." | ( Liu, H; Qian, J; Shen, Q; Shi, WY; Yang, L; Yin, H; Zhang, YP, 2019) |
| "Ruxolitinib is a targeted drug to treat myelofibrosis (MF)." | ( Hu, X; Li, Y; Liu, W; Ming, J; Wang, X; Zhu, S, 2020) |
| "Anemia in myelofibrosis (MF) occurs frequently, is poorly addressed by US Food and Drug Administration-approved JAK inhibitors, and negatively impacts quality of life." | ( Al Ali, N; Castillo-Tokumori, F; Komrokji, R; Kuykendall, AT; Lancet, J; Padron, E; Sallman, D; Sweet, K; Talati, C; Yun, S, 2020) |
| "Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for effective treatments in anemic MF patients." | ( Al-Ali, HK; Cervantes, F; Foltz, L; Gilotti, G; Gisslinger, H; Komatsu, N; Mannelli, F; Myasnikov, A; Palandri, F; Passamonti, F; Radinoff, A; Ross, DM; Sadek, I; Tiwari, R; Vannucchi, AM; Zachee, P; Zor, E, 2021) |
| "Current therapy for myelofibrosis (MF) results in a limited prolongation of patient survival." | ( Clementelli, C; Elmansy, N; Hoffman, R; Lu, M; Tremblay, D; Xia, L, 2022) |
| "Mild-to-moderate bone marrow fibrosis was detected in the posttreatment biopsies of 12/22 patients (54." | ( Akyürek, N; Aydın Kaynar, L; Bostankolu Değirmenci, B; Dikyar, A; Özkurt, ZN; Uyar Göçün, P; Yegin, ZA, 2022) |
| "We report two cases of Primary Myelofibrosis who developed tuberculosis on active treatment with ruxolitinib." | ( Singh, A; Singh, B; Tiwari, N; Tripathi, AK; Verma, SP, 2022) |
| "The haematological assessment revealed myelofibrosis as the underlying disease, and treatment with ruxolitinib as the first-line choice was given by skipping hydroxyurea due to pancytopenia." | ( Deniz, R; Ezircan-Alay, M, 2023) |
| "Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need." | ( Colak, G; Cui, J; Curto-García, N; Devos, T; Granacher, N; Gupta, V; Harrison, C; Hobbs, G; Hoffman, R; Kiladjian, JJ; Kremyanskaya, M; Mascarenhas, J; Mead, AJ; Palandri, F; Passamonti, F; Patriarca, A; Rampal, RK; Salama, ME; Scandura, JM; Somervaille, TCP; Talpaz, M; Vannucchi, AM; Verstovsek, S; Wondergem, MJ, 2023) |
| "People with myelofibrosis who receive treatment with ruxolitinib may need to stop treatment because it is not working or they cannot tolerate the side effects." | ( Mascarenhas, J; McBride, A; Nguyen, H; Oliver, L; Perry, R; Saunders, A; Tomkinson, H, 2023) |
| "The treatment of patients with myelofibrosis (MF) has evolved in the past decade, as reflected in an increased use of various therapeutic agents that could potentially impact patient outcomes." | ( Bose, P; Chifotides, HT; Daver, NG; Estrov, Z; Kantarjian, HM; Masarova, L; Pemmaraju, N; Sasaki, K; Verstovsek, S; Zhou, L, 2023) |
| "Outcomes of myelofibrosis (MF) with allogeneic stem cell transplantation (allo-SCT) have improved over the past decade, related in part to advances in supportive treatments and conditioning regimens." | ( Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA, 2023) |